Latest news with #BrightMindsBiosciences
Yahoo
28-05-2025
- Business
- Yahoo
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
NEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ('Bright Minds,' 'BMB' or the 'Company') (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and Jan Torleif Pedersen, Chief Scientific Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows: Date: Thursday, June 5, 2025 Time: 8:10m ET Webcast: Click Here To schedule a 1x1 meeting with the Company, please contact your Jefferies representative at healthcareconference@ The live and archived webcast will be accessible from the Company's website at under Events and Presentation. The replay of the webcast will be accessible for 60 days. About Bright Minds Biosciences Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives. Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry. Contact Information Investor RelationsLisa M. WilsonT: 212-452-2793E: lwilson@ Alex VasilkevichChief Operating OfficerBright Minds Biosciences Inc.T: 414-731-6422E: alex@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-02-2025
- Business
- Yahoo
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ('Bright Minds,' 'BMB' or the 'Company') (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and select members of senior management, will participate in three healthcare conferences, as follows: TD Cowen 45th Annual Health Care Conference, Boston Monday, March 3, 2025, at 1:10pm ETJoin the webcast Leerink Partners Global Healthcare Conference, MiamiWednesday, March 12, 2025 (1x1 meetings) BIO-Europe Spring, MilanMarch 17-19, 2025 The live and archived webcasts will be accessible from the Company's website at under Events and Presentation. The replay of the webcast will be accessible for 90 days. About Bright Minds Biosciences Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives. Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry. Contact Information Alex VasilkevichChief Operating OfficerBright Minds Biosciences Inc.T: 414-731-6422E: alex@ Investor RelationsLisa M. WilsonT: 212-452-2793E: lwilson@
